IMMURON LIMITED - Announcements

2.94%

7.0¢

Market Cap $18.77M

Healthcare Biotechnology

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMC	IMC Appoints Experienced US Based Biotech Executive as CEO	PRICE SENSITIVE	19/11/18	1.08MB	Share
IMC	NASH clinical trial presentation & continued revenue growth	PRICE SENSITIVE	09/11/18	848.67KB	Share
IMC	Annual Report 2018 on Form 20-F & XBRL data filed with SEC		01/11/18	2.14MB	Share
IMC	IMC's CEO Interviewed in US on the RedChip Money Report		16/10/18	792.22KB	Share
IMC	Notice of Annual General Meeting/Proxy Form		11/10/18	1.36MB	Share
IMC	Notice of Annual General Meeting/Proxy Form		10/10/18	1.35MB	Share
IMC	Corporate Governance Statement		27/09/18	1MB	Share
IMC	Appendix 4G		27/09/18	515.97KB	Share
IMC	Annual Report		27/09/18	1.21MB	Share
IMC	US DoD Report Travelan Protects Against Shigella in Primates	PRICE SENSITIVE	05/09/18	1001.92KB	Share
IMC	Preliminary Final Report	PRICE SENSITIVE	30/08/18	239.38KB	Share
IMC	Initial Director's Interest Notice (RJB)		31/07/18	1.02MB	Share
IMC	Change in substantial holding		30/07/18	152.77KB	Share
IMC	Immuron Reports Record Revenue	PRICE SENSITIVE	25/07/18	872.69KB	Share
IMC	Appendix 3B ESOP		17/07/18	1.14MB	Share
IMC	US Department of Defense Research Collaboration Moves Ahead	PRICE SENSITIVE	16/07/18	881.93KB	Share
IMC	European Patent Gramted for Nash Treatment	PRICE SENSITIVE	11/07/18	782.89KB	Share
IMC	Resignation of Joint Company Secretary		29/06/18	695.6KB	Share
IMC	Immuron Announces Board Appointment	PRICE SENSITIVE	26/06/18	815.87KB	Share
IMC	Trading halt request		25/06/18	541.86KB	Share
IMC	Trading Halt	PRICE SENSITIVE	25/06/18	221.37KB	Share
IMC	IMC Preclinical Study Reports Reduction in Colitis Symptoms	PRICE SENSITIVE	08/05/18	960.7KB	Share
IMC	Immuron CEO to Present at RedChip Global Online Growth Conf		24/04/18	337.71KB	Share
IMC	Travelan Sales Continue to Soar in Third Quarter of FY2018	PRICE SENSITIVE	23/04/18	369.02KB	Share
IMC	Becoming a substantial holder		20/03/18	1.72MB	Share
IMC	ASX Documentation Request - Reduction of Capital (Nov 2017)		19/03/18	10.12KB	Share
IMC	Form 604 - Change in Substantial Shareholding (Grandlodge)		19/03/18	44.16KB	Share
IMC	Appendix 3B & 708A Notice (Placement to US Fund Allotment)		16/03/18	569.86KB	Share
IMC	Immuron Announces A$5.1M Private Placement to U.S. Fund	PRICE SENSITIVE	14/03/18	362.89KB	Share
IMC	Immuron Progresses Discussions with Institutional Funds	PRICE SENSITIVE	13/03/18	349.77KB	Share
IMC	Immuron Commences US Non-Deal Institutional Investor Roadshw		13/03/18	1.54MB	Share
IMC	Trading Halt Request		12/03/18	84.12KB	Share
IMC	Trading Halt	PRICE SENSITIVE	12/03/18	215.65KB	Share
IMC	Immuron Reports Positive Results in NASH Clinical Trial	PRICE SENSITIVE	08/03/18	402.23KB	Share
IMC	Correction to False and Misleading News Release	PRICE SENSITIVE	07/03/18	362.45KB	Share
IMC	Trading Halt	PRICE SENSITIVE	07/03/18	300.18KB	Share
IMC	Appendix 4D - Half Year Financial Report - 31 Dec 2017	PRICE SENSITIVE	28/02/18	261.97KB	Share
IMC	Travelan Revenue Grows Significantly in US and Australia	PRICE SENSITIVE	16/02/18	355.64KB	Share
IMC	IMC Enrols First Patients in IMM529 C. Difficile Study		31/01/18	938.09KB	Share
IMC	US Defence Depart Report-Travelan Targets Priority Pathogens	PRICE SENSITIVE	30/01/18	119.7KB	Share
IMC	Immuron to Receive $2.16M R&D Tax Concession Cash Refund	PRICE SENSITIVE	23/01/18	348.51KB	Share
IMC	Immuron Appoints Grant Thornton as Company Auditors		18/01/18	342.09KB	Share
IMC	CEO to Present on US Investor TV Show and at Biotech Conf		10/01/18	332.87KB	Share
IMC	Form 604 - Change in Substantial Shareholding (Grandlodge)		22/12/17	47.1KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (SA)		22/12/17	47.26KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (PA)		22/12/17	47.11KB	Share
IMC	Appendix 3B		14/12/17	251.99KB	Share
IMC	Van Leeuwenhoeck Institute Updates Immuron Research Coverage		22/11/17	182.36KB	Share
IMC	Immuron Granted US Patent for NASH Treatment	PRICE SENSITIVE	14/11/17	213.3KB	Share
IMC	Results of 2017 Annual General Meeting		13/11/17	275.78KB	Share
IMC	Immuron Successfully Completes NASH Phase II Clinical Study	PRICE SENSITIVE	09/11/17	218.35KB	Share
IMC	Travelan Experiences Strong Q1 FY2018 Sales Growth	PRICE SENSITIVE	08/11/17	333.17KB	Share
IMC	Immuron Lodges Form 20F USA Annual Report		03/11/17	1.97MB	Share
IMC	Notice of Annual General Meeting & Proxy Form		18/10/17	1.11MB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (PA)		10/10/17	122.3KB	Share
IMC	Corporate Governance Statement		28/09/17	537.11KB	Share
IMC	Appendix 4G		28/09/17	421.62KB	Share
IMC	Annual Report		28/09/17	11.87MB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (DP)		11/09/17	490KB	Share
IMC	Form 605 - Ceasing to be Substantial Shareholder (Retzos)		08/09/17	577.86KB	Share
IMC	Appendix 4E Preliminary Final Report (30 June 2017)	PRICE SENSITIVE	31/08/17	1.04MB	Share
IMC	Immuron Opens Clinical Site to Commence C.Diff CDI Study	PRICE SENSITIVE	28/08/17	959.09KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (PA)		28/08/17	490.1KB	Share
IMC	Updated Immuron Securities Trading Policy		17/08/17	127.81KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (PA)		15/08/17	43.93KB	Share
IMC	Immuron Commences US Non-Deal Institutional Investor Roadshw		15/08/17	4.99MB	Share
IMC	Immuron Approved to Commence Clinical Study in C.Difficile	PRICE SENSITIVE	09/08/17	118.99KB	Share
IMC	Immuron to Present C.difficile Data at ClostPath 2017 Confer	PRICE SENSITIVE	08/08/17	354.02KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (PA)		08/08/17	372.34KB	Share
IMC	Immuron Presents NASH Interim-Results at BioShares Conferenc		07/08/17	1.43MB	Share
IMC	Immuron Announces Management Changes	PRICE SENSITIVE	03/08/17	336.18KB	Share
IMC	Appendix 3B		28/07/17	728.08KB	Share
IMC	Success of NASH Phase II Interim Analysis Explained Further	PRICE SENSITIVE	13/07/17	371.05KB	Share
IMC	NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes	PRICE SENSITIVE	10/07/17	347.54KB	Share
IMC	Pre-Clinical C. difficile Infection Results Paper Published	PRICE SENSITIVE	03/07/17	353.77KB	Share
IMC	Appendix 3Y - Change of Director's Interest Notice (RS)		03/07/17	44.05KB	Share
IMC	Change of address		26/06/17	224.22KB	Share
IMC	Appendix 3B - Issuance of Options (ESOP)		23/06/17	732.32KB	Share
IMC	Ceasing to be a substantial holder		20/06/17	749.34KB	Share
IMC	Change in substantial holding		20/06/17	281.72KB	Share
IMC	Change in substantial holding		20/06/17	284.58KB	Share
IMC	Change of Director's Interest Notice		20/06/17	388.93KB	Share
IMC	Change of Director's Interest Notice		20/06/17	374.75KB	Share
IMC	Change of Director's Interest Notice		20/06/17	385.69KB	Share
IMC	Appendix 3B - Allotment of NASDAQ Listing		16/06/17	734.99KB	Share
IMC	IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M	PRICE SENSITIVE	09/06/17	1.11MB	Share
IMC	Trading Halt	PRICE SENSITIVE	08/06/17	297.21KB	Share
IMC	Travelan Increases Industry Presence - Conf & Sales Update	PRICE SENSITIVE	02/06/17	1.12MB	Share
IMC	Immuron Secures $1.5M R&D Cash Advance Loan Funding	PRICE SENSITIVE	01/06/17	1.09MB	Share
IMC	NASDAQ Listing on Hold Pending NASH Interim Analysis Results	PRICE SENSITIVE	01/06/17	1.09MB	Share
IMC	Trading Halt	PRICE SENSITIVE	30/05/17	297.07KB	Share
IMC	IMC Expands Agreement with US Army-3 Additional Therapeutics	PRICE SENSITIVE	16/05/17	1.11MB	Share
IMC	Completion of Manufacturing of Drug Product for C-Diff Trial	PRICE SENSITIVE	10/05/17	1.11MB	Share
IMC	Immuron - New Investor Corporate Presentation (May 2017)		09/05/17	6.66MB	Share
IMC	IMC Form F1 - US Registration Statement (Prelim. Prospectus)	PRICE SENSITIVE	09/05/17	1MB	Share
IMC	Immuron Files Amended Form F-1 and New Investor Presentation		09/05/17	1.07MB	Share
IMC	Form 604 - Change in Substantial Shareholding (Authentics)		05/05/17	102.57KB	Share
IMC	Form 603 - Initial Substantial Shareholder (Authentics)		05/05/17	100.46KB	Share
IMC	Positive Results of IMM-124E in Acute Colitis Studies	PRICE SENSITIVE	18/04/17	1.23MB	Share
IMC	Immuron Update on US Listing - Proceeding as Planned		11/04/17	422.66KB	Share

IMC IMC Appoints Experienced US Based Biotech Executive as CEO
19/11/18	PRICE SENSITIVE	1.08MB	Share
IMC NASH clinical trial presentation & continued revenue growth
09/11/18	PRICE SENSITIVE	848.67KB	Share
IMC Annual Report 2018 on Form 20-F & XBRL data filed with SEC
01/11/18		2.14MB	Share
IMC IMC's CEO Interviewed in US on the RedChip Money Report
16/10/18		792.22KB	Share
IMC Notice of Annual General Meeting/Proxy Form
11/10/18		1.36MB	Share
IMC Notice of Annual General Meeting/Proxy Form
10/10/18		1.35MB	Share
IMC Corporate Governance Statement
27/09/18		1MB	Share
IMC Appendix 4G
27/09/18		515.97KB	Share
IMC Annual Report
27/09/18		1.21MB	Share
IMC US DoD Report Travelan Protects Against Shigella in Primates
05/09/18	PRICE SENSITIVE	1001.92KB	Share
IMC Preliminary Final Report
30/08/18	PRICE SENSITIVE	239.38KB	Share
IMC Initial Director's Interest Notice (RJB)
31/07/18		1.02MB	Share
IMC Change in substantial holding
30/07/18		152.77KB	Share
IMC Immuron Reports Record Revenue
25/07/18	PRICE SENSITIVE	872.69KB	Share
IMC Appendix 3B ESOP
17/07/18		1.14MB	Share
IMC US Department of Defense Research Collaboration Moves Ahead
16/07/18	PRICE SENSITIVE	881.93KB	Share
IMC European Patent Gramted for Nash Treatment
11/07/18	PRICE SENSITIVE	782.89KB	Share
IMC Resignation of Joint Company Secretary
29/06/18		695.6KB	Share
IMC Immuron Announces Board Appointment
26/06/18	PRICE SENSITIVE	815.87KB	Share
IMC Trading halt request
25/06/18		541.86KB	Share
IMC Trading Halt
25/06/18	PRICE SENSITIVE	221.37KB	Share
IMC IMC Preclinical Study Reports Reduction in Colitis Symptoms
08/05/18	PRICE SENSITIVE	960.7KB	Share
IMC Immuron CEO to Present at RedChip Global Online Growth Conf
24/04/18		337.71KB	Share
IMC Travelan Sales Continue to Soar in Third Quarter of FY2018
23/04/18	PRICE SENSITIVE	369.02KB	Share
IMC Becoming a substantial holder
20/03/18		1.72MB	Share
IMC ASX Documentation Request - Reduction of Capital (Nov 2017)
19/03/18		10.12KB	Share
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
19/03/18		44.16KB	Share
IMC Appendix 3B & 708A Notice (Placement to US Fund Allotment)
16/03/18		569.86KB	Share
IMC Immuron Announces A$5.1M Private Placement to U.S. Fund
14/03/18	PRICE SENSITIVE	362.89KB	Share
IMC Immuron Progresses Discussions with Institutional Funds
13/03/18	PRICE SENSITIVE	349.77KB	Share
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw
13/03/18		1.54MB	Share
IMC Trading Halt Request
12/03/18		84.12KB	Share
IMC Trading Halt
12/03/18	PRICE SENSITIVE	215.65KB	Share
IMC Immuron Reports Positive Results in NASH Clinical Trial
08/03/18	PRICE SENSITIVE	402.23KB	Share
IMC Correction to False and Misleading News Release
07/03/18	PRICE SENSITIVE	362.45KB	Share
IMC Trading Halt
07/03/18	PRICE SENSITIVE	300.18KB	Share
IMC Appendix 4D - Half Year Financial Report - 31 Dec 2017
28/02/18	PRICE SENSITIVE	261.97KB	Share
IMC Travelan Revenue Grows Significantly in US and Australia
16/02/18	PRICE SENSITIVE	355.64KB	Share
IMC IMC Enrols First Patients in IMM529 C. Difficile Study
31/01/18		938.09KB	Share
IMC US Defence Depart Report-Travelan Targets Priority Pathogens
30/01/18	PRICE SENSITIVE	119.7KB	Share
IMC Immuron to Receive $2.16M R&D Tax Concession Cash Refund
23/01/18	PRICE SENSITIVE	348.51KB	Share
IMC Immuron Appoints Grant Thornton as Company Auditors
18/01/18		342.09KB	Share
IMC CEO to Present on US Investor TV Show and at Biotech Conf
10/01/18		332.87KB	Share
IMC Form 604 - Change in Substantial Shareholding (Grandlodge)
22/12/17		47.1KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (SA)
22/12/17		47.26KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
22/12/17		47.11KB	Share
IMC Appendix 3B
14/12/17		251.99KB	Share
IMC Van Leeuwenhoeck Institute Updates Immuron Research Coverage
22/11/17		182.36KB	Share
IMC Immuron Granted US Patent for NASH Treatment
14/11/17	PRICE SENSITIVE	213.3KB	Share
IMC Results of 2017 Annual General Meeting
13/11/17		275.78KB	Share
IMC Immuron Successfully Completes NASH Phase II Clinical Study
09/11/17	PRICE SENSITIVE	218.35KB	Share
IMC Travelan Experiences Strong Q1 FY2018 Sales Growth
08/11/17	PRICE SENSITIVE	333.17KB	Share
IMC Immuron Lodges Form 20F USA Annual Report
03/11/17		1.97MB	Share
IMC Notice of Annual General Meeting & Proxy Form
18/10/17		1.11MB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
10/10/17		122.3KB	Share
IMC Corporate Governance Statement
28/09/17		537.11KB	Share
IMC Appendix 4G
28/09/17		421.62KB	Share
IMC Annual Report
28/09/17		11.87MB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (DP)
11/09/17		490KB	Share
IMC Form 605 - Ceasing to be Substantial Shareholder (Retzos)
08/09/17		577.86KB	Share
IMC Appendix 4E Preliminary Final Report (30 June 2017)
31/08/17	PRICE SENSITIVE	1.04MB	Share
IMC Immuron Opens Clinical Site to Commence C.Diff CDI Study
28/08/17	PRICE SENSITIVE	959.09KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
28/08/17		490.1KB	Share
IMC Updated Immuron Securities Trading Policy
17/08/17		127.81KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
15/08/17		43.93KB	Share
IMC Immuron Commences US Non-Deal Institutional Investor Roadshw
15/08/17		4.99MB	Share
IMC Immuron Approved to Commence Clinical Study in C.Difficile
09/08/17	PRICE SENSITIVE	118.99KB	Share
IMC Immuron to Present C.difficile Data at ClostPath 2017 Confer
08/08/17	PRICE SENSITIVE	354.02KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (PA)
08/08/17		372.34KB	Share
IMC Immuron Presents NASH Interim-Results at BioShares Conferenc
07/08/17		1.43MB	Share
IMC Immuron Announces Management Changes
03/08/17	PRICE SENSITIVE	336.18KB	Share
IMC Appendix 3B
28/07/17		728.08KB	Share
IMC Success of NASH Phase II Interim Analysis Explained Further
13/07/17	PRICE SENSITIVE	371.05KB	Share
IMC NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes
10/07/17	PRICE SENSITIVE	347.54KB	Share
IMC Pre-Clinical C. difficile Infection Results Paper Published
03/07/17	PRICE SENSITIVE	353.77KB	Share
IMC Appendix 3Y - Change of Director's Interest Notice (RS)
03/07/17		44.05KB	Share
IMC Change of address
26/06/17		224.22KB	Share
IMC Appendix 3B - Issuance of Options (ESOP)
23/06/17		732.32KB	Share
IMC Ceasing to be a substantial holder
20/06/17		749.34KB	Share
IMC Change in substantial holding
20/06/17		281.72KB	Share
IMC Change in substantial holding
20/06/17		284.58KB	Share
IMC Change of Director's Interest Notice
20/06/17		388.93KB	Share
IMC Change of Director's Interest Notice
20/06/17		374.75KB	Share
IMC Change of Director's Interest Notice
20/06/17		385.69KB	Share
IMC Appendix 3B - Allotment of NASDAQ Listing
16/06/17		734.99KB	Share
IMC IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M
09/06/17	PRICE SENSITIVE	1.11MB	Share
IMC Trading Halt
08/06/17	PRICE SENSITIVE	297.21KB	Share
IMC Travelan Increases Industry Presence - Conf & Sales Update
02/06/17	PRICE SENSITIVE	1.12MB	Share
IMC Immuron Secures $1.5M R&D Cash Advance Loan Funding
01/06/17	PRICE SENSITIVE	1.09MB	Share
IMC NASDAQ Listing on Hold Pending NASH Interim Analysis Results
01/06/17	PRICE SENSITIVE	1.09MB	Share
IMC Trading Halt
30/05/17	PRICE SENSITIVE	297.07KB	Share
IMC IMC Expands Agreement with US Army-3 Additional Therapeutics
16/05/17	PRICE SENSITIVE	1.11MB	Share
IMC Completion of Manufacturing of Drug Product for C-Diff Trial
10/05/17	PRICE SENSITIVE	1.11MB	Share
IMC Immuron - New Investor Corporate Presentation (May 2017)
09/05/17		6.66MB	Share
IMC IMC Form F1 - US Registration Statement (Prelim. Prospectus)
09/05/17	PRICE SENSITIVE	1MB	Share
IMC Immuron Files Amended Form F-1 and New Investor Presentation
09/05/17		1.07MB	Share
IMC Form 604 - Change in Substantial Shareholding (Authentics)
05/05/17		102.57KB	Share
IMC Form 603 - Initial Substantial Shareholder (Authentics)
05/05/17		100.46KB	Share
IMC Positive Results of IMM-124E in Acute Colitis Studies
18/04/17	PRICE SENSITIVE	1.23MB	Share
IMC Immuron Update on US Listing - Proceeding as Planned
11/04/17		422.66KB	Share

REFRESH

First 3 4 5 6 7

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 7.0¢		Change 0.002(2.94%)		Mkt cap ! $18.77M

Open	High	Low	Value	Volume
7.0¢	7.2¢	7.0¢	$16.06K	228.1K

Buyers (Bids)

No.	Vol.	Price($)
1	71437	7.0¢

Sellers (Offers)

Price($)	Vol.	No.
7.2¢	144903	4

View Market Depth

No.	Vol.	Price($)
1	71437	0.070
1	14492	0.069
2	17500	0.068
2	10000	0.067
1	75000	0.066

Price($)	Vol.	No.
0.072	144903	4
0.073	22750	2
0.075	23346	2
0.076	15546	1
0.079	112658	2

Last trade - 15.55pm 08/09/2025 (20 minute delay)

IMC (ASX) Chart

IMMURON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available